# Kyverna Therapeutics (KYTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/KYTX
## Company Profile
- Ticker: KYTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Immunology
## Stock Data
- Close: 8.05 USD
- Market cap: 480282174.8 USD
- Last updated: 2026-08-12
## Business Overview
### Autoimmune CAR T Company
Kyverna Therapeutics develops autologous CD19-directed CAR T-cell therapy for B-cell-driven autoimmune diseases.
### Miv-cel
Mivocabtagene autoleucel, or miv-cel, is a fully human CAR T therapy designed to produce deep B-cell depletion after a single administration.
### Stiff Person Syndrome
The pivotal KYSA-8 study supports the first planned BLA for an autoimmune CAR T therapy in stiff person syndrome.
### Broader Autoimmune Development
Kyverna is also advancing miv-cel in generalized myasthenia gravis and other autoimmune disorders.
## Why The Stock Is Moving

The latest company update was “Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results”. KYTX changed 0.37% and closed at $8.05 on Aug 12, 2026, indicating a relatively limited closing-price reaction to this earnings update.

## Future Catalysts

- Completion of the rolling miv-cel BLA submission in stiff person syndrome is expected in the fourth quarter of 2026.

## Recent News
- 2026-08-11 20:02 EST — [Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-reports-pipeline-progress-and-second-quarter-2026-financial-a365a33b) — Source: Kyverna Therapeutics
- 2026-07-27 12:00 EST — [Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel](https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-and-elevatebio-enter-into-commercial-manufacturing-and-supp-297d17c6) — Source: Kyverna Therapeutics
- 2026-06-22 12:00 EST — [Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition](https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-appoints-ritesh-srivastava-as-chief-legal-and-compliance-of-eb83a070) — Source: Kyverna Therapeutics
- 2026-06-03 12:00 EST — [Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis](https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-highlights-updated-miv-cel-data-at-eular-demonstrating-subs-5e700d3e) — Source: Kyverna Therapeutics
- 2026-05-18 12:00 EST — [Kyverna Therapeutics Names Greg Martini as Chief Financial Officer](https://biopharmsignal.com/news/KYTX/kyverna-therapeutics-names-greg-martini-as-chief-financial-officer-526628e6) — Source: Kyverna Therapeutics